Global Innovative Platforms Inc.

Global Innovative Platforms Inc. reported its first revenue of $106,500 for the three months ended March 31, 2026, and $136,500 for the six months, primarily from an agreement involving its VOCAM Plus diagnostic technology. The company significantly increased its cash and cash equivalents to $327,270 and reduced its net cash used in operating activities. Despite this progress, the company continues to operate at a net loss and its financial statements include a "going concern" explanatory paragraph.

Global Innovative Platforms Inc. announced the appointment of four new directors to its Board, effective April 1, 2026, increasing the board size from one to four members. The new directors are Elyssa Jacob Campbell, James C. Jones, Anthony Porter, and David Mauer. These appointments bring diverse expertise in animal health research, legal and compliance, healthcare operations, business development, and partnership management, aligning with the company's strategic focus on innovative breath-based diagnostics for animal health.